<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01644747</url>
  </required_header>
  <id_info>
    <org_study_id>N/2011/60</org_study_id>
    <nct_id>NCT01644747</nct_id>
  </id_info>
  <brief_title>tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients</brief_title>
  <acronym>STICODEP</acronym>
  <official_title>tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients: a Randomized, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Investigation Centre for Innovative Technology Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Le Vinatier - Service de Psychiatrie (Dr Emmanuel POULET)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EPS Ville-Evrard - Unité de Recherche Clinique (Dr Dominique JANUEL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Civil de Strasbourg - Service de Psychiatrie (Pr G.Bertschy)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to investigate the effect of transcranial Direct Current Stimulation (tDCS)
      applied at the anodal left CDLPF of patients with resistant depression compared to patients
      treated with conventional therapy. The tDCS is used in add-on drug treatment in resistant
      depression stabilized for 4 weeks (antidepressant as SSRIs (Selective Serotonin Reuptake
      Inhibitors) or SNRIs (Serotonine-Norepinephrine Reuptake Inhibitors) for unipolar patients
      and lithium for bipolar patients). The delay of 4 weeks is a minimum to observe a
      non-response. Moreover, in term of ethical point of view, it's difficult to wait 6 to 8 weeks
      to observe the non-response to treatment.

      This is a randomized 2-arm parallel, double blind study comparing 2 groups of 60 patients (48
      unipolar plus 12 bipolar patients per group. Patients will be selected in the psychiatric
      department of the University Hospital of different centers and the two groups are matched for
      age (+/- 5 years), gender and depression diagnosis (unipolar vs bipolar).

      After giving informed consent, patients will be evaluated by a psychiatrist using the
      Hamilton Depression Rating Scale (HDRS), Montgomery Asberg Depression Rating Scale (MADRS),
      the STAI and Beck Depression Inventory (BDI) and for bipolar patient only, by the Young Mania
      Rating Scale (YMRS). The complete assessment takes 50 minutes. A neuropsychologist assessment
      will be also realized during 20 minutes using the Crossing of Test (COT), the Trail Making
      Test (TMT), the Isaacs Set Test (IST) and the Cardebat fluency Task.

      After locating the left DLPFC, treatment with active tDCS with a current of 2 mA or sham will
      be directed by 30-minute session. A psychometric assessment will be conducted again at the
      end of treatment week and 4, 12 and finally 24 weeks after stopping treatment. The
      neuropsychologist assessment will be conducted again 4 weeks after the end of treatment.
      Scales of comfort and acceptability will also be proposed to the patient to determine whether
      any gene is caused by this treatment.

      These people will be recruited on a voluntary basis, after notification and consent in the 6
      research centers. This study was conducted over a period of 36 months.

      This study was supporting by a grant from the French Hospital Program of Clinical Reseach
      (PHRC N/2011-60-2011-A01074-37)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in HDRS-21 scale</measure>
    <time_frame>baseline, 1 wk, 2 wk, 4wk, 12 wk, 24 wk</time_frame>
    <description>The changes in HDRS-21 will constitute the major research outcome measure used to assess response to tDCS. Response to treatment is defined as a ≥ 50% reduction in the scores of the HDRS. Remission is defined as a HDRS score ≤ 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MADRS, BDI, HAMA, STAI, YMRS</measure>
    <time_frame>baseline, 1 wk, 2 wk, 4wk, 12 wk, 24 wk</time_frame>
    <description>Montgomery and Asberg Depression Rating Scale (MADRS) Beck Depression Inventory-13 (BDI) Subscores for anxiety depression scale from HDRS-21 State-Trait Anxiety Inventory (STAI) Young Mania Rating Scale (YMRS) : only for bipolar patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in COT, TMT, IST and Cardebat fluency task</measure>
    <time_frame>baseline, 4wk</time_frame>
    <description>Crossing of test (COT) Trail Making test (TMT) Isaacs Set Test (IST) Cardebat fluency task</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Resistant Depression</condition>
  <condition>Moods Disorders</condition>
  <condition>Unipolar Depression</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>active tDCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a group named G1 and treated by medication with SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonine-Norepinephrine Reuptake Inhibitors) for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and 10 sessions of active anodal tDCS at 2 sessions per day (1 morning and 1 afternoon with a gap of 3h) for 5 days with an electric current 2 mA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>a group named G2 and treated by medication with SSRIs or SNRIs for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and sham tDCS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)</intervention_name>
    <description>After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.</description>
    <arm_group_label>active tDCS</arm_group_label>
    <arm_group_label>sham tDCS</arm_group_label>
    <other_name>EldithDC-NeuroConn Stimulator (NeuroConn Gmbh, Ilmenau, Germany)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject whose MDD are single or recurrent without psychotic features according to
             DSM-IV-TR

          -  subject with a diagnosis of resistant major depression (≥1 failed antidepressant
             treatments for the current depressive episode)

          -  HDRS-21 score ≥ 21

          -  drug treatment by SSRIs or SNRIs for unipolar patients or with Lithium for bipolar
             patients for at least 4 weeks

          -  right-handed patients

          -  without severe progressive somatic pathology (especially tumor diseases, degenerative
             diseases)

          -  without severe cognitive impairment making psychometric evaluation impossible

          -  excepted antidepressant or Lithium treatment, psychotropic following are tolerated
             during the course of the study : hydroxyzin; cyamemazin (up to 100 mg/day) ; hypnotics
             (imidazopyridin).

        Exclusion Criteria:

          -  subject treated with antipsychotics or mood stabilizers or anticonvulsants or by ECT
             or rTMS for the current depressive episode

          -  subject resistant to SSRIs or SNRIs for unipolar patients or with Lithium for bipolar
             patients

          -  subject with mixed features

          -  pregnancy and/or lactation

          -  presence of a specific contraindication for tDCS (e.g., personal history of epilepsy,
             metallic head implant, cardiac pacemaker)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel HAFFEN, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel HAFFEN, Prof</last_name>
    <phone>+33381218154</phone>
    <email>emmanuel.haffen@univ-fcomte.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magali NICOLIER, PhD</last_name>
    <phone>+33381219007</phone>
    <email>mnicolier@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Besancon - Service de Psychiatrie - Centre Investigation Clinique Innovation Technologique (CIC-IT808)</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel HAFFEN, Prof</last_name>
      <phone>+33381218154</phone>
      <email>emmanuel.haffen@univ-fcomte.fr</email>
    </contact>
    <contact_backup>
      <last_name>Magali NICOLIER, PhD</last_name>
      <phone>+33381219007</phone>
      <email>mnicolier@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel HAFFEN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - Clinique de Psychiatrie de l'Adulte</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mircea POLOSAN, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>David SZEKELY, MD</last_name>
      <email>DSzekely@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>David SZEKELY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Vinatier - Service de Psychiatrie</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel POULET, MD</last_name>
      <email>EMMANUEL.POULET@ch-le-vinatier.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel POULET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Guillaume Régnier - Rennes - Service Hospitalo-Universitaire de Psychiatrie</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique DRAPIER, MD PhD</last_name>
      <email>d.drapier@ch-guillaumeregnier.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique DRAPIER, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil de Strasbourg - Service de Psychiatrie</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles BERTSCHY, MD PhD</last_name>
      <email>gilles.bertschy@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles BERTSCHY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Etablissement Public de Santé Mentale - Unité de Recherche Clinique</name>
      <address>
        <city>Ville Evrard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique JANUEL, MD</last_name>
      <email>d.januel@eps-ville-evrard.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexane STEPHAN</last_name>
      <email>a.stephan@epsve.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Dominique JANUEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2012</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resistant Depression</keyword>
  <keyword>Moods disorders</keyword>
  <keyword>Unipolar depression</keyword>
  <keyword>Bipolar disorder</keyword>
  <keyword>tDCS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

